157 related articles for article (PubMed ID: 26806466)
1. An elastic liposomal formulation for RNAi-based topical treatment of skin disorders: Proof-of-concept in the treatment of psoriasis.
Desmet E; Bracke S; Forier K; Taevernier L; Stuart MC; De Spiegeleer B; Raemdonck K; Van Gele M; Lambert J
Int J Pharm; 2016 Mar; 500(1-2):268-74. PubMed ID: 26806466
[TBL] [Abstract][Full Text] [Related]
2. Towards the development of a RNAi-based topical treatment for psoriasis: Proof-of-concept in a 3D psoriasis skin model.
Desmet E; Van Gele M; Grine L; Remaut K; Lambert J
Exp Dermatol; 2018 May; 27(5):463-469. PubMed ID: 28833576
[TBL] [Abstract][Full Text] [Related]
3. Characterization data on the topical carrier DDC642.
Desmet E; Bracke S; Forier K; Taevernier L; Stuart MC; De Spiegeleer B; Raemdonck K; Van Gele M; Lambert J
Data Brief; 2016 Jun; 7():1204-10. PubMed ID: 27408923
[TBL] [Abstract][Full Text] [Related]
4. RNAi mediated IL-6 in vitro knockdown in psoriasis skin model with topical siRNA delivery system based on liquid crystalline phase.
Depieri LV; Borgheti-Cardoso LN; Campos PM; Otaguiri KK; Vicentini FT; Lopes LB; Fonseca MJ; Bentley MV
Eur J Pharm Biopharm; 2016 Aug; 105():50-8. PubMed ID: 27224855
[TBL] [Abstract][Full Text] [Related]
5. Development of edge-activated liposomes for siRNA delivery to human basal epidermis for melanoma therapy.
Dorrani M; Garbuzenko OB; Minko T; Michniak-Kohn B
J Control Release; 2016 Apr; 228():150-158. PubMed ID: 26965957
[TBL] [Abstract][Full Text] [Related]
6. Identifying targets for topical RNAi therapeutics in psoriasis: assessment of a new in vitro psoriasis model.
Bracke S; Desmet E; Guerrero-Aspizua S; Tjabringa SG; Schalkwijk J; Van Gele M; Carretero M; Lambert J
Arch Dermatol Res; 2013 Aug; 305(6):501-12. PubMed ID: 23775225
[TBL] [Abstract][Full Text] [Related]
7. Liposomal siRNA delivery.
Hughes J; Yadava P; Mesaros R
Methods Mol Biol; 2010; 605():445-59. PubMed ID: 20072900
[TBL] [Abstract][Full Text] [Related]
8. Dendrimer as a new potential carrier for topical delivery of siRNA: A comparative study of dendriplex vs. lipoplex for delivery of TNF-α siRNA.
Pandi P; Jain A; Kommineni N; Ionov M; Bryszewska M; Khan W
Int J Pharm; 2018 Oct; 550(1-2):240-250. PubMed ID: 30165098
[TBL] [Abstract][Full Text] [Related]
9. Preparation, characterization, and
Walunj M; Doppalapudi S; Bulbake U; Khan W
J Liposome Res; 2020 Mar; 30(1):68-79. PubMed ID: 30897993
[TBL] [Abstract][Full Text] [Related]
10. Novel nanosome delivery system combined with siRNA targeting the antimicrobial gene DFB4: a new approach for psoriasis management?
Keren A; David M; Gilhar A
Exp Dermatol; 2014 Jul; 23(7):464-5. PubMed ID: 24673207
[TBL] [Abstract][Full Text] [Related]
11. Topical delivery of siRNA into skin using SPACE-peptide carriers.
Chen M; Zakrewsky M; Gupta V; Anselmo AC; Slee DH; Muraski JA; Mitragotri S
J Control Release; 2014 Apr; 179():33-41. PubMed ID: 24434423
[TBL] [Abstract][Full Text] [Related]
12. Targeted silencing of DEFB4 in a bioengineered skin-humanized mouse model for psoriasis: development of siRNA SECosome-based novel therapies.
Bracke S; Carretero M; Guerrero-Aspizua S; Desmet E; Illera N; Navarro M; Lambert J; Del Rio M
Exp Dermatol; 2014 Mar; 23(3):199-201. PubMed ID: 24428418
[TBL] [Abstract][Full Text] [Related]
13. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing.
Cardoso AL; Simões S; de Almeida LP; Pelisek J; Culmsee C; Wagner E; Pedroso de Lima MC
J Gene Med; 2007 Mar; 9(3):170-83. PubMed ID: 17351968
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells.
Taetz S; Bochot A; Surace C; Arpicco S; Renoir JM; Schaefer UF; Marsaud V; Kerdine-Roemer S; Lehr CM; Fattal E
Oligonucleotides; 2009 Jun; 19(2):103-16. PubMed ID: 19374532
[TBL] [Abstract][Full Text] [Related]
15. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
DeVincenzo JP
Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
[TBL] [Abstract][Full Text] [Related]
16. CXCL1 gene silencing in skin using liposome-encapsulated siRNA delivered by microprojection array.
Haigh O; Depelsenaire AC; Meliga SC; Yukiko SR; McMillan NA; Frazer IH; Kendall MA
J Control Release; 2014 Nov; 194():148-56. PubMed ID: 25192942
[TBL] [Abstract][Full Text] [Related]
17. Chapter 17 - Engineering cationic liposome siRNA complexes for in vitro and in vivo delivery.
Podesta JE; Kostarelos K
Methods Enzymol; 2009; 464():343-54. PubMed ID: 19903563
[TBL] [Abstract][Full Text] [Related]
18. Lipoplexes versus nanoparticles: pDNA/siRNA delivery.
Khurana B; Goyal AK; Budhiraja A; Aora D; Vyas SP
Drug Deliv; 2013 Feb; 20(2):57-64. PubMed ID: 23537464
[TBL] [Abstract][Full Text] [Related]
19. Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS.
Cardoso AL; Simões S; de Almeida LP; Plesnila N; Pedroso de Lima MC; Wagner E; Culmsee C
J Control Release; 2008 Dec; 132(2):113-23. PubMed ID: 18796321
[TBL] [Abstract][Full Text] [Related]
20. A fast and sensitive method for measuring the integrity of siRNA-carrier complexes in full human serum.
Buyens K; Lucas B; Raemdonck K; Braeckmans K; Vercammen J; Hendrix J; Engelborghs Y; De Smedt SC; Sanders NN
J Control Release; 2008 Feb; 126(1):67-76. PubMed ID: 18068258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
